media1

Zprávy skupiny

  • Department of Health and PHEF celebrate investment in human resources
    on 01.05.2019

    The South African National Department of Health (NDoH) and the Public Health Enhancement Fund (PHEF) celebrated their investment in human resources for health in honour of the late Prof Bongani Mayosi on 30 April 2019. The public and private healthcare sector leaders and professionals converged in honour of post-graduate and medical doctors from various healthcare… The post Department of Health and PHEF celebrate investment in human resources appeared first on Aspen Pharmacare. …

    >> Read more

  • Aspen approved for secondary listing on A2X
    on 25.03.2019

    Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has been approved for a secondary listing on A2X Markets with effect from 1 April 2019. Stephen Saad, Aspen Group Chief Executive said, “We continually strive to identify ways to increase value for our shareholders and the complementary A2X… The post Aspen approved for secondary listing on A2X appeared first on Aspen Pharmacare. …

    >> Read more

  • Aspen’s encouraging Emerging Market growth
    on 08.03.2019

    Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced interim financial results for the six months ended 31 December 2018 in line with management’s expectations. Stephen Saad, Aspen Group Chief Executive said, “Revenue increases from Anaesthetics in China and Latin America of 6% and 22% respectively… The post Aspen’s encouraging Emerging Market growth appeared first on Aspen Pharmacare. …

    >> Read more

  • Aspen launches novel ARV Combination: Set to further improve treatment options
    on 26.11.2018

    Johannesburg: Aspen Pharmacare, South Africa’s leading JSE-listed pharmaceutical company, is pleased to announce the launch of EmdoltenTM, a Dolutegravir-based triple combination anti-retroviral (ARV) treatment option. EmdoltenTM, a once a day triple combination tablet therapy in the form of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate, is positioned to become a preferred first line ARV and will… The post Aspen launches novel ARV Combination: Set to further improve treatment options appeared first on Aspen Pharmacare. …

    >> Read more

  • Aspen’s participation in the 2018 Investment Conference
    on 26.10.2018

    Sandton – Aspen welcomes President Ramaphosa’s inaugural Investment Conference, aimed at positioning South Africa as a preferred investment destination and at establishing a more predictable and stable investment environment in our country. Amongst other initiatives, this includes facilitating the ease of doing business and reducing unnecessary regulatory burden in the South African pharmaceutical sector. These… The post Aspen’s participation in the 2018 Investment Conference appeared first on Aspen Pharmacare. …

    >> Read more